<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188887</url>
  </required_header>
  <id_info>
    <org_study_id>P140931</org_study_id>
    <secondary_id>2016-004507-31</secondary_id>
    <nct_id>NCT03188887</nct_id>
  </id_info>
  <brief_title>Treatment of IgA Nephropathy According to Renal Lesions</brief_title>
  <acronym>TIGER</acronym>
  <official_title>Treatment of IgA Nephropathy According to Renal Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TIGER study (Treatment of IgA nEphropathy according to Renal lesions) is a prospective openly&#xD;
      randomized controlled study.&#xD;
&#xD;
      The main objective is to evaluate the efficacy of early corticotherapy + RAS blockade (versus&#xD;
      RAS blockade alone) after two years of evolution in IgAN patients with severe histological&#xD;
      lesions The study will include 122 IgAN patients, it is scheduled to start in september 2017.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, IgAN treatment recommendations are only based on clinico-biological parameters.&#xD;
      Steroids therapy appears to have a major role in IgAN treatment, but previous studies&#xD;
      evaluating steroids lacked of optimal control group and reproducible evaluation criteria. No&#xD;
      prospective study with optimal RAS blockade had included renal pathology in patients&#xD;
      selection criteria, although histological evaluation improves patients prognosis prediction.&#xD;
      Until now, the lack of a reliable histological classification has precluded the use of&#xD;
      histological lesions to evaluate IgAN prognosis and treatment. Given the recently identified&#xD;
      major prognostic role of histological lesions in IgAN, we propose to introduce renal&#xD;
      pathology to guide the treatment of IgAN in a multicenter study, using currently validated&#xD;
      evaluation criteria of chronic kidney disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">February 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure at 24 months</measure>
    <time_frame>Month 24</time_frame>
    <description>Failure at 24 months will be defined as :&#xD;
Proteinuria/creatinuria ratio (PCR) &gt; 0,5 g/g&#xD;
or mGFR &lt; 80% of initial mGFR (or eGFR if unavailable)&#xD;
or loss of more than 10 ml/min/1,73m2 of initial mGFR (or eGFR if unavailable)&#xD;
or end stage renal disease (ESRD)&#xD;
or renal transplantation&#xD;
or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure at 6 months</measure>
    <time_frame>Month 6</time_frame>
    <description>Failure at 6 months will be defined as:&#xD;
PCR &gt; 0.75 g/g&#xD;
or PCR &gt; 0.5 g/g and &gt;30% of initial PCR&#xD;
or eGFR &lt; 80% of initial eGFR&#xD;
or end stage renal disease (ESRD)&#xD;
or renal transplantation&#xD;
or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>Failure at 12 months will be defined as:&#xD;
PCR &gt; 0.75 g/g&#xD;
or PCR &gt; 0.5 g/g and &gt; 30% of initial PCR&#xD;
or mGFR &lt; 80% of initial mGFR (or eGFR if unavailable)&#xD;
or end stage renal disease (ESRD)&#xD;
or renal transplantation&#xD;
or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with persistent severe histological lesions in repeat kidney biopsy at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>to compare the evolution of histological lesions between treatment groups at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of GFR at 12 months assessed as :- the absolute value of GFR - the absolute difference of GFR from the baseline - the annual degradation (ml/min /1,73m2/year) of GFR during the 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>to compare the evolution of measured GFR (mGFR) between treatment groups at 12 months (or estimated GFR (eGFR) if unavailable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of GFR at 24 months assessed as :- the absolute value of GFR - the absolute difference of GFR from the baseline - the annual degradation (ml/min /1,73m2/year) of GFR during the 24 months</measure>
    <time_frame>Month 24</time_frame>
    <description>to compare the evolution of measured GFR (mGFR) between treatment groups at 24 months (or estimated GFR (eGFR) if unavailable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of proteinuria assessed as : - the absolute value of proteinuria at 12 and 24 months - the absolute difference of proteinuria from baseline at 12 and 24 months</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>to compare the evolution of proteinuria in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 scale at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>to compare the quality of life in each therapeutic group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 scale at 24 months</measure>
    <time_frame>Month 24</time_frame>
    <description>to compare the quality of life in each therapeutic group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects</measure>
    <time_frame>Month 24</time_frame>
    <description>to assess the tolerance of treatments in each therapeutic group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis markers of failure at 24 months</measure>
    <time_frame>Month 24</time_frame>
    <description>Clinical, histological, and biological data (including PCR ratio, eGFR and mGFR, renal histological lesions) will be compared between patients with or without failure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Renin Angiotensin system (RAS) blockade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPERIMENTAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corticotherapy + RAS blockade treatment. Drug injection (intravenous) + tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticotherapy</intervention_name>
    <description>3 IV pulses steroids followed by oral steroids for 4 months</description>
    <arm_group_label>EXPERIMENTAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renin Angiotensin system (RAS) blockade</intervention_name>
    <description>treatment with Renin angiotensin system (RAS) blockade</description>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_label>EXPERIMENTAL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;= 18 years&#xD;
&#xD;
          2. Patient with IgAN&#xD;
&#xD;
          3. Renal biopsy &lt; 45 days before inclusion visit&#xD;
&#xD;
          4. PCR ratio &gt;0.75 g/g (within 30 days before or after the renal biopsy)&#xD;
&#xD;
          5. Renal biopsy with at least 8 glomeruli, disclosing at least 2 criteria among:&#xD;
&#xD;
               -  mesangial proliferation (according to Oxford criteria)&#xD;
&#xD;
               -  endocapillary proliferation (according to Oxford criteria)&#xD;
&#xD;
               -  tubulointerstitial fibrosis (according to Oxford criteria) &gt;25% of the biopsy&#xD;
&#xD;
               -  segmental glomerulosclerosis (according to Oxford criteria)&#xD;
&#xD;
               -  at least 1 cellular/fibrocellular crescents (C1 according to Oxford criteria)&#xD;
&#xD;
          6. Patient with Social Security Insurance or CMU&#xD;
&#xD;
          7. Patient having signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. &gt;30% increase of serum creatinine after starting RAS blockade therapy (≥ 15 days and ≤&#xD;
             6 weeks) only for patient under RAS &lt;45 days of the inclusion visit&#xD;
&#xD;
          2. &gt;50% cellular/fibrocellular crescents, or &gt;50% tubulointerstitial fibrosis or &gt;50%&#xD;
             globally sclerotic glomeruli&#xD;
&#xD;
          3. Nephrotic syndrome with minimal change disease and IgA deposits&#xD;
&#xD;
          4. eGFR &lt;20 ml/min/1,73m2 (CKD-EPI formula) within 30 days before or after the renal&#xD;
             biopsy&#xD;
&#xD;
          5. Uncontrolled blood pressure (Systolic blood pressure &gt;180 mmHg or diastolic blood&#xD;
             pressure &gt; 110 mmHg)&#xD;
&#xD;
          6. Previous corticosteroids treatment (&gt;20 mg/d during more than 15 days, within the last&#xD;
             3 months before the renal biopsy)&#xD;
&#xD;
          7. Pregnancy or breast feeding or women without sufficient contraception&#xD;
&#xD;
          8. Secondary known forms of IgAN&#xD;
&#xD;
          9. Henoch-Schoenlein purpura&#xD;
&#xD;
         10. Additional other chronic renal disease&#xD;
&#xD;
         11. Contraindication for immunosuppressive therapy, including active intestinal bleeding,&#xD;
             active gastric or duodenal ulcer; active infection; any malignancy in a last years&#xD;
             before the inclusion; severe psychiatric disease; living vaccines; anti-inflammatory&#xD;
             dosages of acetylsalicylic acid&#xD;
&#xD;
         12. Contraindication for RAS blockade therapy&#xD;
&#xD;
         13. Known allergy or intolerance to corticoids or lactose&#xD;
&#xD;
         14. Organ transplant patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique JOLY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric ALAMARTINE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khalil El Karoui</last_name>
    <role>Study Chair</role>
    <affiliation>Henri Mondor University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique JOLY, MD, PhD</last_name>
    <phone>+33 1 44 49 54 12</phone>
    <email>dominique.joly@nck.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra COLAS</last_name>
    <phone>01 71 19 64 32</phone>
    <email>sandra.colas@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker Enfants-malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique JOLY, MD, PhD</last_name>
      <phone>+33 1 44 49 54 12</phone>
      <email>dominique.joly@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NIgA</keyword>
  <keyword>Kidney biopsy</keyword>
  <keyword>GFR</keyword>
  <keyword>Corticotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

